Press Releases Latest May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting Press Releases Year None202420232022202120202019201820172016201520142013 Oct 06, 2021 Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference Sep 29, 2021 Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021 Sep 22, 2021 Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study Sep 16, 2021 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021 Sep 07, 2021 Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science Aug 04, 2021 Theratechnologies to Present at the Canaccord Genuity 41st Annual Growth Conference Jul 23, 2021 Theratechnologies Establishes New At-The-Market Facility Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH First page « Previous page ‹ … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Next page › Last page » Displaying 101 - 110 of 361
May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Sep 16, 2021 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021
Sep 07, 2021 Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH